Semaglutide

PSI Assessment

The treatment landscape for obesity changed when a single medication demonstrated both sustained weight loss and cardiovascular risk reduction in the same clinical program. Semaglutide, sold as Ozempic, Wegovy, and Rybelsus, is FDA-approved across three indications with more than 40,000 randomized trial participants supporting those approvals. The clinical questions are no longer whether it works. They are how it compares to newer dual and triple receptor agonists, what happens to weight after stopping treatment, and how to manage the common gastrointestinal side effects.

More than 40,000 randomized trial participants. A 20% reduction in cardiovascular events in people with obesity and heart disease. The evidence base is the deepest in the peptide space.

Research Evidence

The findings below cover what the clinical programs established and where the evidence still has gaps.

39 Human|121 Animal|40 Reviews

How Semaglutide Works

Semaglutide is a modified version of GLP-1, a hormone your body naturally releases after eating. It has two key changes from the native hormone that let it stay in the bloodstream for about a week instead of a few minutes.

Think of GLP-1 as a fullness signal your body sends after a meal. Semaglutide amplifies that signal so it lasts much longer than normal. Your brain receives a stronger message that you have eaten enough. At the same time, your stomach empties more slowly, so food stays with you longer. The combined effect is that you eat less without feeling like you are fighting hunger.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

Semaglutide is a 94% amino acid homolog of human GLP-1(7-37) with two modifications: an Aib substitution at position 8 that resists enzymatic degradation, and a fatty diacid chain attached at Lys26 that promotes binding to albumin in the blood. These modifications extend the half-life to approximately seven days, allowing once-weekly dosing. It activates the GLP-1 receptor on pancreatic beta cells (enhancing glucose-dependent insulin release), alpha cells (suppressing glucagon), hypothalamic neurons (reducing appetite), and gastric smooth muscle (slowing gastric emptying). Central nervous system effects on reward pathways may reduce food-seeking behavior independently of satiety signaling.

What is Semaglutide being studied for?

Researchers are studying Semaglutide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Semaglutide overall. This means a compound can have human studies for one condition but only animal data for another.

Safety and Regulatory Status

Common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are dose-dependent and generally transient but can limit tolerability. The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies; this has not been observed in humans. A 2026 retrospective study (Liu et al., J Clin Endocrinol Metab) reported modest bone mineral density loss in semaglutide and tirzepatide users tied to weight loss. Bone density loss was similar to matched controls in patients with diabetes; in non-diabetic users, the GLP-1 RA group lost modestly more at the total hip (-1.0% vs -0.6% over 17 months). The pattern is consistent with bariatric surgery and severe caloric restriction, suggesting the effect is weight-loss-mediated rather than a direct drug action. Adults at baseline fracture risk, including post-menopausal women, older adults, and anyone with prior osteopenia or osteoporosis, should discuss bone density monitoring with their physician. 1,5

Questions and Comparisons

Questions the evidence raises for a Semaglutide discussion.